| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8770264 | Journal of Renal Nutrition | 2018 | 8 Pages |
Abstract
Iron administration to patients on MHD with severe iron deficiency decreased C-FGF23 levels, whereas intravenous iron increased I-FGF23 levels though oral iron did not. If the target of chronic kidney disease-mineral and bone disorder therapy is reducing I-FGF23 levels, we suggest the use of oral iron.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Wataru MD, Yukiko MD, PhD, Tomo MD, Kazuhiro MD, Makoto MD, Satoko MD, Mari MD, Shoko (Ikeda) MD, Takahide MD, Mana MD, Masatoshi MD, PhD, Yasuyuki MD, PhD, Takahiro MD, PhD, Takeshi MD, PhD,